The first study to directly compare immune reactions between Pfizer’s and AstraZeneca’s Covid-19 vaccines found strong and broadly similar antibody responses in over-80-year-olds after a first dose of either shot, scientists said on April 14.
Covid-19 was the primary or contributing cause of 377,883 deaths in the United States during 2021, with a particularly high toll among the elderly, according to a government report released on March 31.
The majority of people who have had Covid-19 are protected from getting it again for at least six months, a study published on March 17 showed, but older people are more prone to reinfection than younger people.
GlaxoSmithKline will extend a trial testing an experimental rheumatoid arthritis drug on patients suffering from pneumonia related to Covid-19 to focus on the elderly as the company seeks to firm up encouraging findings.
Oxford University and AstraZeneca’s Covid-19 vaccine showed in a study it had 76% efficacy against symptomatic infection for three months after a single dose, which increased if the second shot is delayed, backing Britain’s vaccine rollout policy.
AstraZeneca denied the company’s Covid-19 vaccine is not very effective for people over 65 years old, after German media reports said officials fear the vaccine may not be approved in the European Union for use in the elderly.
Moderna Inc.’s coronavirus vaccine mRNA-1273 became the second to receive emergency use authorization (EUA) from the U.S. Food and Drug Administration, welcome news to a nation with a staggering Covid-19 death toll of more than 307,000 lives lost.
The United States authorized the use of Pfizer Inc’s Covid-19 vaccine on Dec. 11, with the first inoculations expected within days, marking a turning point in a country where the pandemic has killed more than 295,000 people.
A roundup of some of the latest scientific studies on the novel coronavirus includes research on whether a childhood vaccine may help prevent severe Covid-19 and whether cigarette smoke increases cell vulnerability to Covid-19.
GlaxoSmithKline will move the company’s experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing after experiencing encouraging mid-stage trial results.